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ABSTRACT
Objective: To evaluate the incremental cost-effectiveness ratio (ICER) of
switching to ezetimibe/simvastatin (Eze/Simva) compared with doubling
the submaximal statin doses, in patients with acute coronary syndrome
(ACS) events in the INFORCE study.
Methods: Lifetime treatment costs and beneﬁts were computed using a
Markov model. Model inputs included each patient’s cardiovascular risk
factor proﬁle and actual lipid values at baseline and 12 weeks (endpoint).
Cardiovascular event and drug costs were discounted at 3.5%. Age-
speciﬁc utilities were based on UK literature values and non–coronary
heart disease mortality rates on the Ofﬁce of National Statistics data. In
the INFORCE study, 384 patients taking statins at stable doses for 6
weeks before hospital admission were stratiﬁed by statin dose/potency
(low, medium, and high) and then randomized to doubling the statin dose
or switching to Eze/Simva 10/40 mg for 12 weeks.
Results: The Eze/Simva group (n = 195) had a higher mean baseline total
cholesterol than the double-statin group (n = 189). Analyses were adjusted
for baseline characteristics. In the INFORCE study, Eze/Simva reduced
low-density lipoprotein cholesterol (LDL-C) by ~30% (vs. 4% with dou-
bling statin doses) and signiﬁcantly enhancedLDL-C goal attainment. In the
cost-effectiveness analysis, Eze/Simva conferred 0.218 incremental dis-
counted quality-adjusted life year (QALY) at a discounted incremental cost
of £2524, for an ICER of £11,571/QALY (95% conﬁdence interval =
£8181–£18,600/QALY). The ICER was £13,552/QALY, £11,930/
QALY, and £10,148/QALY in the low-, medium-, and high-potency strata,
respectively.
Conclusions: Switching to Eze/Simva 10/40 mg is projected to be a cost-
effective treatment (vs. double-statin) in UK patients with ACS.
Keywords: coronary disease, cost-effectiveness, drug therapy, ezetimibe,
hydroxymethylglutaryl CoA reductase inhibitors (statins), hypercholester-
olemia, prevention and control.
Introduction
Cardiovascular disease is the leading modiﬁable cause of mortal-
ity in the western industrialized world. In the United States, 37 of
every 100 deaths (>900,000) each year are ascribed to cardio-
vascular disease as an underlying cause [1]. By one estimate, 56%
of ischemic heart disease worldwide can be ascribed to elevated
total cholesterol (TC) [2]. In the United Kingdom, cardiovascular
disease is also the main cause of death, accounting for nearly
200,000 fatalities, or 30% of premature deaths in men and 22%
in women annually [3]. Each year, up to 146,000 British adults
experience myocardial infarctions (MIs), and the total annual
cost of coronary heart disease (CHD)–related disease burdens in
the United Kingdom is approximately £7 billion [4,5]. Cardio-
vascular disease costs Europe €190 billion each year (2006) [6].
Hyperlipidemia, which includes elevations in low-density
lipoprotein cholesterol (LDL-C), represents a pivotal modiﬁable
risk factor to prevent cardiovascular disease [7–9]. For every 1%
decrease in LDL-C, the cardiovascular event rate declines by
approximately 1% [10]. Statin therapy reduced the 5-year inci-
dence of major vascular (coronary) events by 21% (and of
ischemic stroke by 19%) per 1-mmol/l reduction in LDL-C
(largely irrespective of baseline cholesterol) [11]. Randomized
controlled trials have demonstrated that the magnitude of reduc-
tion in absolute coronary risk in patients with CHD (or at
advanced CHD risk [12,13]) is directly proportional to the abso-
lute reduction in LDL-C on treatment. The landmark UK Heart
Protection Study (HPS) documented signiﬁcant reductions in car-
diovascular events and mortality after simvastatin treatment
[14–16]. The Scandinavian Simvastatin Survival Study (4S) also
demonstrated signiﬁcant cardioprotective beneﬁts of daily simv-
astatin 10–40 mg, which signiﬁcantly reduced the relative risk of
all-cause mortality by 30% versus placebo (P = 0.0003) over 5.4
years in patients with a history of acute MI or angina pectoris
[17].
Research ﬁndings such as these [18–20] have provided the
foundation for an overall treatment strategy of “lower (LDL-C)
is better,” particularly in patients with CHD (e.g., acute coronary
syndrome [ACS]). For these patients, US and European consen-
sus panels have recommended consideration of more stringent
LDL-C targets, on the order of <1.8 mmol/l (<70 mg/dl) to
<2.0 mmol/l (<80 mg/dl) “if feasible.” (For a comprehensive
review, see Catapano [21].) Despite these increasingly aggressive
cholesterol treatment targets, numerous recent studies have dem-
onstrated that most patients with CHD or elevated cardiovascu-
lar risk do not achieve even less stringent guideline targets
[22–27]. Regimens in many of these studies comprised statin
monotherapy at low- to medium-dose potency, with infrequent
adjustment of doses despite suboptimal goal achievement and
infrequent prescription of combination regimens.
Given that cardiovascular mortality in the United Kingdom is
among the highest of all countries in Western Europe, the gov-
ernment has resolved to lower the mortality rate from CHD and
stroke in people ages <75 years by 40% by 2010 (the target has
already been met), saving approximately 200,000 lives in total
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[28,29]. UK guidelines have recommended the use of statins in all
patients with a 10-year cardiovascular risk of 20% [8]. The
General Medical Services contract [30] requires general practi-
tioners to increase efforts to use lipid-lowering treatments in
secondary prevention and offers ﬁnancial incentives. Neverthe-
less, reports from the Health Survey for England have docu-
mented improved, yet still decidedly suboptimal, treatment and
control rates for lipids between 1998 and 2003 [31]. A 2002
survey revealed that nearly 70% of adults had TC 5 mmol/l,
and the mean TC level was 5.47 mmol/l (212 mg/dl) in men and
5.59 mmol/l (216 mg/dl) in women [32].
In light of these trends, novel clinical strategies are warranted
to achieve increasingly aggressive consensus treatment targets.
Combination therapies with potentially complementary mecha-
nisms of action include 3-hydroxy-3-methylglutaryl-coenzyme A
(HMG-CoA) reductase inhibitors (i.e., statins) with niacin (nico-
tinic acid), or with a ﬁbric-acid (ﬁbrate) derivative. A third
option for adjunctive therapy to enhance lipid effects and cho-
lesterol goal attainment is dual cholesterol inhibition, including a
statin, such as simvastatin (Simva), to inhibit the rate-limiting
enzyme in hepatic cholesterol biosynthesis (HMG-CoA reduc-
tase) and ezetimibe (Eze; Ezetrol, Zetia; Merck, Whitehouse
Station, NJ) to inhibit intestinal absorption of cholesterol
[33,34].
Treatment with Eze/Simva (Inegy, Vytorin; Merck) is associ-
ated with signiﬁcant improvements in lipid levels and LDL-C
goal achievement and is well tolerated (vs. up-titrating statin
doses [35–38]). In a recent European study involving patients
with CHD and/or type 2 diabetes mellitus, individuals whose
treatments were switched from atorvastatin 10 mg to Eze/Simva
10/20 mg were ~6 times more likely to achieve LDL-C treat-
ment targets (vs. doubling the atorvastatin dose; [odds
ratio = 5.7; 95% conﬁdence interval [CI] = 3.7–9.0; P < 0.0001]
[37]). Other clinical studies have demonstrated that Eze/Simva
treatment is associated with signiﬁcantly enhanced LDL-C–
lowering (and LDL-C goal-achieving) effects (vs. statin mono-
therapy) across a broad spectrum of patient populations
[35,37,39–41].
The INFORCE trial (lipid-altering efﬁcacy of Inegy com-
pared with doubling the statin dose [i.e., double-statin group]) in
adults admitted to the hospital for suspected (and later proven)
ACS events was a phase IV, randomized, open-label study con-
ducted from January 2005 through June 2007 at 48 sites in 14
countries [36]. It evaluated the effects on LDL-C of switching to
Eze/Simva 10/40 mg compared with doubling the existing statin
dose (i.e., double-statin group). The study demonstrated that
switching to Eze/Simva 10/40 mg was associated with signiﬁ-
cantly reduced LDL-C, TC, apolipoprotein B (apoB), non–high-
density lipoprotein cholesterol (non–HDL-C), and both
TC : HDL-C and LDL-C : HDL-C ratios compared with dou-
bling the statin dose (P  0.001 for each between-group differ-
ence) [36]. Further, patients whose regimens were switched to
Eze/Simva were about twice as likely to achieve aggressive
LDL-C treatment targets as their counterparts in the double-
statin group (P  0.001 for each between-group difference).
Moreover, whether the patients were previously on a low-,
medium-, or high-potency statin, Eze/Simva consistently pro-
duced greater improvements in lipids with a similar safety proﬁle
compared with doubling the dose of statins [35]. The purpose of
the present analysis was to estimate the incremental cost-
effectiveness ratio (ICER) for patients in the INFORCE trial (all
patients and per statin dose strata) of switching to Eze/Simva (vs.
doubling a submaximal statin dose) by translating improvements
in lipids (observed TC : HDL-C ratio) into projected lifetime
costs and beneﬁts.
Methods
Data Source:The INFORCE Study [36]
The design/timeline of the INFORCE study (Merck/Schering-
Plough Protocol 808; NCT00132717; http://clinicaltrials.gov/
archive/NCT00132717/2009_04_13) has been previously
described [36]. Study subjects were hospitalized for suspected
(and later proven) ACS events and had been using a stable
(submaximal) dose of a statin for 6 weeks before admission.
After being discharged, patients were stratiﬁed into 3 levels of
statin doses of approximately equal mg : mg LDL-C–lowering
potencies. These included stratum 1, low-potency (ﬂuvastatin
40 mg; pravastatin 10 and 20 mg; Simva 10 mg); stratum 2,
medium-potency (atorvastatin 10 mg; Simva 20 mg); and stratum
3, higher-potency (atorvastatin 20 and 40 mg; rosuvastatin 10 and
20 mg; and Simva 40 mg). Patients were randomized in a 1:1 ratio
to either switch to Eze/Simva 10/40 mg or to double the statin
dose,with treatment for 12weeks. At the 12-week visit, Eze/Simva
10/40 mg lowered LDL-C by 27.0% compared with 4.2% in the
double-statin group, for an incremental reduction of 22.8%.
Cost-Effectiveness Model Structure
A Markov decision-analytic model was used to project lifetime
beneﬁts and costs of lipid-lowering therapy [42]. This model was
applied to estimate the costs and beneﬁts for each patient of
different lipid-lowering therapies. According to the model, Eze
potentiates the LDL-C–lowering capacity of statin therapy by a
further 23.2% (vs. statin monotherapy). On the other hand,
doubling the dose of statin therapy or switching to an alternative
statin is associated with further decrements in LDL-C concentra-
tions of approximately 6% and 8%, respectively [43,44]. The
model compared the cost-effectiveness of switching treatment to
Eze/Simva 10/40 mg with remaining on a statin and doubling its
dose.
Costs and health outcomes of lipid-lowering treatment were
captured in a Markov process with a cycle length of 1 year. Five
health states were included: no event, MI, angina pectoris, CHD
death, or non–CHD death (Fig. 1) [42]. Stroke was not included
in the analysis. Each health state was assigned an expected cost.
The probability of moving from one health state to another
during a given year depends on current health status and cardio-
vascular risk factor proﬁles. These risk proﬁles were used to
compute the annual risks of fatal and nonfatal CHD events
according to risk equations derived from the Framingham Heart
Study [45,46] as well as the annual risk of non–CHD death using
UK-speciﬁc mortality data [47]. The model took a payor (UK
Department of Health) perspective.
Model Inputs: INFORCE Patient Data
To estimate the ICER of switching to Eze/Simva 10/40 mg com-
pared with doubling the statin dose, differences in treatment
costs and beneﬁts for each individual were estimated from the
baseline and 12-week follow-up lipid measures. Patients from the
INFORCE study were considered eligible for the economic
analysis if they were included in the primary efﬁcacy analysis.
The comparative effects of switching to Eze/Simva or dou-
bling the statin dose were reﬂected in observed alterations in each
respondent’s actual lipid levels at baseline and endpoint in the
INFORCE trial [36]. The effects of different treatments, includ-
ing Eze/Simva 10/40 mg and statins at various potencies and
doses, on changes from baseline to endpoint in lipids were
entered into the Markov model on a per-patient basis, with
treatment costs and beneﬁts being computed for each patient at
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baseline and endpoint. Lipid alterations modiﬁed each partici-
pant’s CHD risk and the likelihood of moving between or among
different health states over time, each of which has an assigned
cost (year 2004 costs in £, scaled to 2009 costs). Treatment
conferred long-term beneﬁts measured as quality-adjusted life
years (QALYs) according to established time trade-offs (i.e.,
utilities).
Cost Data and Cost-Utility Weights
Each patient’s risk factor proﬁle and observed baseline and end-
point lipid values were used to project the long-term costs (£) and
beneﬁts for each individual (Table 1). Inputs for cardiovascular
events were scaled to 2008 costs. Age-speciﬁc utilities for health
states were based on the Cook et al. model [42]. Non–CHD
death rates from 2006 were obtained from the UK Ofﬁce for
National Statistics [47] to estimate age-speciﬁc non–CHD mor-
tality. Both costs and beneﬁts of medications were discounted at
3.5% based on National Institute for Clinical Excellence (NICE)
guidelines for economic evaluations [48]. Although the
INFORCE study involved a single tablet of Eze/Simva (Inegy®),
the cost of this treatment (and all others) was computed using the
lowest cost alternatives: ezetimibe plus generic simvastatin. The
time horizon for the model was lifetime up to a potential age of
Age 1 year:
update risk
factors
Calculate risk of
Non-CHD death
and CHD
Enter:
new patient with
prior CHD
Cholesterol
intervention
program
Fatal event:
Non-CHD death,
CHD death
Nonfatal event:
recurrent MI,
recurrent angina
No CHD event:
no event last year,
MI last year, angina
last year
Figure 1 Model structure [42]. Flow chart for
Markov model of cost-effectiveness in preventing
coronary heart disease (CHD). MI, myocardial
infarction.
Table 1 Model inputs: summary of event and treatment costs
Parameter
Value, £, First year
(subsequent years) Note
Annual event costs*
Nonfatal MI 4823.29 (185.43) Palmer et al. [84] inﬂated to 2004 (£4118) + primary care and medication cost for
angina pectoris (£440)
Stable angina pectoris 185.43 (185.43) Three contacts with GPs for 15 minutes each +medication costs
Unstable angina 477.12 (185.43) First year: stable angina costs + costs of 60% of patients using clopidogrel; Subsequent
years: 3 contacts with GPs for 15 minutes each +medication costs (subsequent year)
Fatal CHD 1264.38 (NA) Clarke et al. [85] inﬂated to 2004
Daily prescription costs
Simvastatin (generic) (mg)
10 0.03 Dept of Health Drug Tariff 03/09 [86]
20 0.03 Dept of Health Drug Tariff 03/09 [86]
40 0.05 Dept of Health Drug Tariff 03/09 [86]
80 0.10 Dept of Health Drug Tariff 03/09 [86]
Atorvastatin (Lipitor) (mg)
10 0.64 Dept of Health Drug Tariff 03/09 [86]
20 0.88 Dept of Health Drug Tariff 03/09 [86]
40 0.88 Dept of Health Drug Tariff 03/09 [86]
80 1.01 Dept of Health Drug Tariff 03/09 [86]
Pravastatin (generic) (mg)
10 0.06 Dept of Health Drug Tariff 03/09 [86]
20 0.08 Dept of Health Drug Tariff 03/09 [86]
40 0.10 Dept of Health Drug Tariff 03/09 [86]
Fluvastatin† (mg)
40 (Lescol) 0.55 Dept of Health Drug Tariff 03/09 [86]
80 (Lescol extended-release) 0.69 Dept of Health Drug Tariff 03/09 [86]
Rosuvastatin (Crestor) (mg)
10 0.64 Dept of Health Drug Tariff 03/09 [86]
20 0.93 Dept of Health Drug Tariff 03/09 [86]
40 1.06 Dept of Health Drug Tariff 03/09 [86]
Ezetimibe 10 (Ezetrol) 0.94 Dept of Health Drug Tariff 03/09 [86]
*Event costs were adjusted for inﬂation. †No patient in the analysis received ﬂuvastatin 20 mg.
CHD, coronary heart disease; MI, myocardial infarction; NA, not applicable; GP, general practitioner.
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100 years. A sensitivity analysis was conducted on projected
costs and beneﬁts assuming an acquisition price of generic ator-
vastatin equivalent to generic simvastatin.
Statistical Analysis
Results were reported for costs and beneﬁts of therapies in year-
2004 British pounds (£; discounted and undiscounted), as well as
mean ICER with 95% CI. Analyses of incremental costs and
beneﬁts of switching to Eze/Simva (vs. double-statin) were
adjusted for baseline characteristics because of between-group
imbalances of LDL-C and TC levels. To estimate the variability
of these ICER values, bootstrap resampling of the patients’ pro-
jected lifetime costs and beneﬁts was conducted. Bootstrapping is
a well-established method for estimating variability of ICER
measures, particularly in the presence of skewed data [49–55].
The bootstrap method is an empirical method that makes no
assumptions about the sampling distribution of the ICER; rather,
the method generates an empirical distribution of the ICER based
on repeated sampling of the costs and effects from each indi-
vidual INFORCE study participant [56,57]. Sampling was per-
formed while retaining the distribution of the number of patients
in each treatment by stratum of statins of doses of equivalent
potency. One thousand bootstrap samples were selected, and the
mean costs and QALYs were calculated for each iteration. The
upper and lower bounds for the conﬁdence interval for the ICER
were computed by excluding the upper and lower 2.5% of the
sampling distribution.
Results
Baseline Characteristics
In the INFORCE study population, 201 patients were included in
the Eze/Simva group and 195 in the double-statin group. Of
these, 6 patients in each treatment arm who were receiving
lovastatin were excluded because lovastatin is not available/
reimbursed in the United Kingdom, resulting in a total of 384
patients included in the present analysis: 195 in the Eze/Simva
group and 189 in the double-statin group. The distribution of
different statins in the 3 groups has been previously described
[36]. In this population, patients in the Eze/Simva 10/40 mg
group had higher baseline LDL-C and TC levels than their coun-
terparts in the double-statin group (Table 2). There was also a
slightly higher proportion of patients with diabetes mellitus in
the Eze/Simva group.
Costs and Beneﬁts of Therapy
Table 3 summarizes the projected undiscounted and discounted
lifetime costs and beneﬁts of switching to Eze/Simva therapy (vs.
double-statin) at baseline and follow-up.
In a pooled-data analysis of all patients and patients in dif-
ferent statin strata, switching to Eze/Simva was associated with a
projected incremental discounted lifetime cost of £2524 and an
incremental discounted beneﬁt of 0.218 QALY (Table 4). Con-
sequently, the estimated ICER (95% CI) was £11,571/QALY
(£8181–£18,600/QALY; Fig. 2). Switching from a statin at sub-
maximal dose to Eze/Simva 10/40 mg was projected to be a
cost-effective treatment alternative to continuing to use the statin
and doubling its dose, with an ICER value <£14,000/QALY in
each statin dose/potency stratum: £13,552/QALY in stratum 1
(low-potency); £11,930/QALY in stratum 2 (mid-potency), and
£10,148/QALY in stratum 3 (high-potency).
Discussion
According to the results from our Markov model, switching to
Eze/Simva 10/40 mg is projected to be a cost-effective treatment
alternative to doubling the current statin dose among UK inpa-
tients being evaluated for suspected (and later proven) ACS
events. The cost-effectiveness of statins in settings of primary, and
especially secondary, coronary prevention, including in a hospital
setting among patients with evolving ACS [58], has been dem-
onstrated [59–66]. A previous study suggested that adding
ezetimibe to a statin was cost-effective (vs. statin monotherapy)
[67]. In this study, the cost-effectiveness of treating patients with
Eze/statins (vs. statin monotherapy with doubling of the statin
dose) improved as a function of increasing CHD risk [67], given
that ICER values decreased with increasing statin dose potency,
which is in turn commonly construed as a surrogate for increased
cardiovascular risk. On the other hand, a recent study in the
United Kingdom using a Markov model projected that, in a
hypothetical population of 1000 men aged 55 years with cardio-
vascular disease, adding Eze to a statin conferred 134 additional
QALYs and averted 43 nonfatal MIs, 7 nonfatal strokes, and 26
cardiovascular deaths over the population’s total lifespan, com-
pared with doubling the statin dose; these data were consistent
with an ICER value of £27,475/QALY compared with statin
monotherapy up-titrated by 1 dose [68]. The ICER increased to
£32,000/QALY among men aged 75 years. As in our analysis,
these UK investigators reported that ICERs were well below
£20,000/QALY for the comparison of Eze/Simva (generic) com-
pared with branded atorvastatin in patients with established
cardiovascular disease; however, the comparison of Eze/
atorvastatin (branded) with branded rosuvastatin, which was not
examined in our study, resulted in ICER values exceeding
£30,000/QALY [68].
In the UK and other parts of Europe, most patients do not
achieve guideline-recommended lipid levels [24,26]. Indeed, most
clinicians initiate treatment with low- to mid-potency statins.
Many make no further dose adjustments (i.e., “ﬁre and forget”),
others up-titrate the statin monotherapy dose, and even fewer
switch to a potentially complementary/synergistic adjunctive
therapeutic approach, even in the face of suboptimal goal attain-
ment. The European Action on Secondary Prevention through
Intervention to Reduce Events II (EUROASPIRE II) survey ﬁnd-
ings revealed that most high-risk patients were inadequately
Table 2 Descriptive summary of patient proﬁles by treatment group
Variable
Eze/Simva
10/40 mg
Double
statin dose
N = 195 N = 189
Age, mean (SD), year 63.3 (10.5) 63.6 (10.9)
% female 20.0 18.5
Systolic blood pressure, mmHg, mean (SD) 130.6 (15.7) 131.7 (17.5)
% using hypertensive meds 98.0 98.4
% smokers 18.5 19.0
% with diabetes mellitus 27.7 25.9
Number of patients by strata
Low-potency statin 30 24
Mid-potency statin 71 72
High-potency statin 94 93
Baseline lipids, mmol/l, mean (SD)
LDL-C 2.46 (0.76) 2.29 (0.68)
HDL-C 1.08 (0.27) 1.08 (0.27)
Triglycerides 1.73 (0.76) 1.73 (0.67)
Total cholesterol 4.33 (0.89) 4.16 (0.80)
Follow-up lipids, mmol/l, mean (SD)
LDL-C 1.80 (0.68) 2.21 (0.85)
HDL-C 1.19 (0.31) 1.16 (0.30)
Triglycerides 1.61 (0.86) 1.62 (0.77)
Total cholesterol 3.71 (0.83) 4.12 (0.99)
Eze, ezetimibe; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol; SD, standard deviation; Simva, simvastatin.
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treated, and only one-ﬁfth of patients with hyperlipidemia
received lipid-lowering drugs. Half of patients on medications
did not attain their cholesterol targets, and most of those using
lipid-lowering therapies received suboptimal doses [69]. Simi-
larly, the French Registry of Acute ST-elevation or non-ST-
elevation Myocardial Infarction (FAST-MI) study demonstrated
that, even though statins are widely used in France, their use is
still suboptimal; outcomes could perhaps be improved by closer
adherence to current treatment guidelines [70].
In the United Kingdom, NICE guidelines are to use generic
simvastatin 40 mg as primary treatment [71]. These guidelines
support up-titration of statin doses in secondary (to simvastatin
80 mg) but not primary prevention. The NICE guidelines also
allow for the addition of ezetimibe to a generic statin under
secondary prevention scenarios as being more cost-effective than
switching to nongeneric full-dose statin [71]. NICE guidelines for
familial hypercholesterolemia also recognize the need for a
potent statin, often with addition of ezetimibe, in order to
achieve a minimum of 50% LDL-C lowering [72]. Our ﬁndings
add further support for these recommendations that adding
ezetimibe to statin therapy, as opposed to doubling the statin
dose, may be both more efﬁcacious and cost-effective.
Table 3 Summary of projected lifetime costs and beneﬁts by treatment and strata*
Group Variable
Eze/Simva 10/40 mg
N = 195
Double statin dose
N = 189
Baseline Follow-up Baseline Follow-up
Pooled data† Undiscounted
Mean cost, £ 6,469 10,554 6,396 6,825
Mean life-years 15.71 16.80 15.84 16.24
Mean QALYs 9.44 10.08 9.50 9.73
Discounted*
Mean cost, £ 4,602 7,398 4,491 4,763
Mean life-years 11.24 11.83 11.25 11.47
Mean QALYs 6.82 7.17 6.82 6.94
Stratum 1 (low-potency) Undiscounted
Mean cost, £ 4,701 9,805 5,264 5,369
Mean life-years 14.64 15.75 16.51 16.83
Mean QALYs 8.76 9.40 9.91 10.10
Discounted*
Mean cost, £ 3,372 6,965 3,667 3,725
Mean life-years 10.03 11.25 11.55 11.72
Mean QALYs 6.42 6.78 7.00 7.10
Stratum 2 (medium-potency) Undiscounted
Mean cost, £ 5,223 10,315 5,750 6,242
Mean life-years 15.35 16.47 16.12 16.41
Mean QALYs 9.15 9.79 9.76 9.92
Discounted*
Mean cost, £ 3,522 7,300 3,994 4,308
Mean life-years 11.07 11.69 11.33 11.49
Mean QALYs 6.66 7.02 6.94 7.03
Stratum 3 (high-potency) Undiscounted
Mean cost, £ 7,974 10,973 7,189 7,652
Mean life-years 16.32 17.39 15.45 15.96
Mean QALYs 9.89 10.51 9.20 9.49
Discounted*
Mean cost, £ 5,625 7,610 5,088 5,384
Mean life-years 11.55 12.12 11.11 11.39
Mean QALYs 7.08 7.41 6.67 6.84
Analysis assuming cost of generic
simvastatin for atorvastatin
Undiscounted
Mean cost, £ 4,838 10,554 4,863 5,066
Mean life-years 15.71 16.80 15.84 16.24
Mean QALYs 9.44 10.08 9.50 9.73
Discounted*
Mean cost, £ 3,431 7,398 3,430 3,550
Mean life-years 11.24 11.83 11.25 11.47
Mean QALYs 6.82 7.17 6.82 6.94
*All costs and beneﬁts were discounted at 3.5%.
†Pooled data are for all patients and for patients in different strata of statin potency.
Eze, ezetimibe; QALY, quality-adjusted life-year; Simva, simvastatin.
Table 4 Incremental cost-effectiveness ratios (ICERs) for switching to ezetimibe-simvastatin 10/40 mg compared with doubling the statin dose*
Statin treatment stratum
Incremental
discounted* cost, £
Incremental
discounted* QALY
ICER, discounted,*
£/QALY
Pooled 2,524 0.218 11,571
Low-potency 3,535 0.261 13,552
Medium-potency 3,220 0.270 11,930
High-potency 1,689 0.166 10,148
Assuming cost of generic
simvastatin for atorvastatin
3,842 0.218 17,616
*Analyses were adjusted for baseline characteristics.All costs and beneﬁts were discounted at 3.5%.
QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio.
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Potential Study Limitations
Limitations of this study include the fact that the relatively lower
cost-effectiveness in the low- and medium-potency statin strata
appears to have been driven by the imbalance in risk proﬁles,
particularly the TC and LDL-C values, across these strata at
baseline. Although the marginal distributions suggest that the
groups were well balanced, CHD risk is a function of the joint
distributions of several parameters. Consequently, baseline risk
functions were not completely balanced, and small differences in
estimated QALYs could have exerted a substantial impact on
ICER values. However, across all statin strata, the ﬁndings were
similar after adjusting for the imbalances in baseline cholesterol
levels between the treatment alternatives.
The model took a payor (UK Department of Health) perspec-
tive and hence captured only direct costs. The ﬁndings are most
generalizable to other patient populations similar to the
INFORCE population: recently hospitalized patients with ACS
who initially received statins at stable, submaximal doses. In
addition, cost-effectiveness depends on a wide range of clinical
factors in each population; price differences and other cost dif-
ferentials in Europe, or even within different countries within
Western Europe, can result in widely divergent cost-effectiveness
estimates [73,74]. The model was also based on medication
effects on surrogate endpoints, in that the INFORCE study did
not determine comparative effects of Eze/Simva (vs. double-
statin) on clinical or angiographic endpoints [36]. In particular,
reductions in the risk of CHD for Eze were estimated based on
changes in lipid components from Framingham risk equations.
Studies to demonstrate the efﬁcacy of Eze (or the incremental
efﬁcacy of Eze/statins over statins) on clinical outcomes have not
been completed.
Another limitation is that, unlike the case with intensive
statin therapy, the effectiveness of Eze/Simva in reducing cardio-
vascular events has not been demonstrated. An analysis of the
Global Registry of Acute Coronary Events (GRACE) study found
that patients with an ACS who had LDL-C levels <100 mg/dl
were much less likely to be prescribed statin therapy at hospital
discharge [75]. However, these patients are expected to derive
similar beneﬁts from statins as those with higher LDL-C levels.
The INFORCE study evaluated the lipid-lowering efﬁcacy of
Eze/Simva compared with statin monotherapy with doubling of
doses [36]. Another study demonstrated that, in patients with
acute MI, Eze/Simva lowered LDL-C levels more effectively than
simvastatin alone [76]. Though these studies did not assess long-
term outcomes, there is a well-established relation between
LDL-C and cardiovascular outcomes. Presumably, lowering
lipids with Eze/Simva reduces adverse cardiovascular outcomes.
An outcomes trial (IMProved Reduction of Outcomes: Vytorin
Efﬁcacy International Trial [IMPROVE-IT]; NCT#00202878
[77]) is ongoing, and empirical results regarding this principle are
expected in June 2013. The central objective of this trial is to
compare the effects of treatment with Eze/Simva and simvastatin
monotherapy on the primary outcome measure of death because
of any cardiovascular event, nonfatal coronary events, and non-
fatal stroke.
The cost of stroke was not included in our analysis. By not
including stroke in our cost estimates, hence we adopted a con-
servative posture, provided that equal percent of LDL-C reduc-
tions provide approximately equal percent relative risk
reductions. A meta-analysis demonstrated that statins reduced
the incidence of total stroke but had little effect on fatal stroke
[78]. Similarly, a more recent meta-analysis demonstrated that
statins were the most effective cholesterol-lowering treatment to
decrease the risk of total stroke, with the beneﬁts being propor-
tional to the percent reduction in TC and LDL-C. However, no
lipid-lowering intervention was associated with a signiﬁcant
reduction in the incidence of fatal stroke [79]. By omitting stroke
prevention from the beneﬁts of lipid-lowering therapy, we might
have underestimated total cost savings (if the higher proportion-
ate LDL-C reductions with Eze/Simva [vs. double-statin doses]
indeed translated into more pronounced decreases in the inci-
dence of stroke). However, prospective, randomized, double-
blind trials are needed to conﬁrm or reject the premise that
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the 95% conﬁdence interval for the ICER.
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Eze/Simva confers more marked cerebrovasculoprotective effects
compared with doubling an equidose statin.
Certain model assumptions are potentially open to challenge,
including the assumption of 100% long-term treatment adher-
ence over the lifetime. Finally, inputs for cardiovascular disease
were scaled to 2008 costs, transitions among health states over
time were in year-2004 costs scaled to 2009 costs, and non–CHD
mortality death rates were from 2006. These discrepancies would
not be expected to exert a signiﬁcant systematic effect on the
comparative cost-effectiveness data for Eze/Simva compared with
statin monotherapy with doubling of the dose. Another consid-
eration is the potential instability of cholesterol levels in the face
of evolving ACS (although cholesterol ratios seem to be stable
[80]). Further, the actual cardiovascular risk of our UK high-risk
population might differ from the calculated risk based on the
Framingham risk equation [81–83].
Conclusion
Among UK residents who are evaluated in the hospital for sus-
pected (and later proven) ACS events and initially receive statin
monotherapy at submaximal doses, switching to Eze/Simva
10/40 mg is projected to be cost-effective at <£14,000/QALY
when compared with continuing to use the statin and doubling
its dose. These ﬁndings may help to inform clinical and health-
care policy decision-making.
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